Refine
Is part of the Bibliography
- yes (155)
Year of publication
Document Type
- Journal article (126)
- Doctoral Thesis (28)
- Preprint (1)
Keywords
- heart failure (16)
- echocardiography (9)
- Herzinsuffizienz (8)
- cardiomyopathy (6)
- magnetic resonance imaging (6)
- mitochondria (6)
- acute heart failure (5)
- myocardial infarction (5)
- prognosis (5)
- akute Herzinsuffizienz (4)
- atrial fibrillation (4)
- cardiovascular genetics (4)
- ischemic stroke (4)
- mortality (4)
- Barth syndrome (3)
- Herzhypertrophie (3)
- Herzmuskelkrankheit (3)
- MRI (3)
- Magnetic resonance imaging (3)
- chronic heart failure (3)
- deep learning (3)
- desmin (3)
- hypertension (3)
- radial (3)
- reactive oxygen species (3)
- 7 T (2)
- 7T (2)
- Arrhythmie (2)
- Beschleunigungssensor (2)
- CRISPR/Cas9 (2)
- Chronotrope Inkompetenz (2)
- DSG2 (2)
- EUROASPIRE (2)
- Fabry disease (2)
- Fluoreszenz (2)
- GFAP (2)
- Guidelines (2)
- Heart failure (2)
- Herzfrequenz (2)
- Herzmuskelzelle (2)
- Herzschrittmacher (2)
- Induzierte pluripotente Stammzelle (2)
- Koronare Herzkrankheit (2)
- Mitochondrium (2)
- Natrium-Calcium-Austauscher (2)
- Pulswelle (2)
- Quality of life (2)
- TRP-Kanäle (2)
- TRPC4 (2)
- accelerometer-sensor (2)
- anxiety (2)
- arrhythmia (2)
- arrhythmogenic cardiomyopathy (2)
- atherosclerosis (2)
- biomarkers (2)
- carbohydrates (2)
- cardiac (2)
- cardiac device (2)
- cardiac magnetic resonance (2)
- cardiac magnetic resonance imaging (2)
- cardiac metabolism (2)
- cardiogenetics (2)
- cardiolipin (2)
- cardiology (2)
- cardiovascular diseases (2)
- cardiovascular implantable electronic device (2)
- cardiovascular risk factors (2)
- chronotropic incompetence (2)
- cognitive impairment (2)
- coronary heart disease (2)
- depression (2)
- desmosomes (2)
- diabetes mellitus (2)
- diffusion tensor imaging (2)
- dilated cardiomyopathy (2)
- ejection fraction (2)
- glial fibrillary acidic protein (2)
- heart (2)
- heart rate (2)
- inflammation (2)
- internal medicine (2)
- left ventricular ejection fraction (2)
- mapping (2)
- morbidity (2)
- mouse (2)
- myocardial work (2)
- neural networks (2)
- norepinephrine transporter (2)
- positron emission tomography (2)
- quality (2)
- quality of life (2)
- regulatory T cells (2)
- respiratory chain (2)
- restrictive cardiomyopathy (2)
- secondary prevention (2)
- segmentation (2)
- theranostics (2)
- thorax (2)
- translational research (2)
- troponin (2)
- whole exome sequencing (2)
- 3D echocardiography (1)
- 3D printing (1)
- 3 T (1)
- 4D flow MRI (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- ACC/AHA classification (1)
- ACM (1)
- AHF (1)
- AHF-Register Würzburg (1)
- AI (1)
- ARVC (1)
- ASE formula (1)
- Acylcarnitin (1)
- Addison's disease (1)
- Alzheimer's disease (1)
- Angiotensin II (1)
- Aorta (1)
- Aortenklappe (1)
- Arrhythmogene Kardiomyopathie (1)
- Arrhythmogenic cardiomyopathy (1)
- Arterielle Gefäßsteifigkeit (1)
- Arteriosklerose (1)
- Asthma (1)
- Atherosclerosis (1)
- B (1)
- B-MYB (1)
- B0 (1)
- BDNF (1)
- Barth Syndrome (1)
- Bildgebendes Verfahren (1)
- Biobank (1)
- Bioluminescence (1)
- Blood pressure (1)
- Brain atrophy (1)
- Breathing (1)
- Brownian ratchet (1)
- Bypass (1)
- CD4+ T-cells (1)
- CMR (1)
- COVID-19 (1)
- CRISPR-Cas Systems (1)
- CRISPR/Cas-Methode (1)
- CXCR4 (1)
- Calcium (1)
- Calciumkanal (1)
- Calciumtransport (1)
- Calpain (1)
- Cardiac (1)
- Cardiac Efficiency (1)
- Cardiac MRI (1)
- Cardiac ventricles (1)
- CardioMEMS™ HF system (1)
- CardioMEMS™ HF-System (1)
- Cardiovascular disease (1)
- Cardiovascular diseases (1)
- Cardiovascular magnetic-resonance (1)
- Carotis Intima Media Dicke (1)
- Cavβ subunit (1)
- Cerebral-ischemia (1)
- Chronic heart failure (1)
- Chronic heart-failure (1)
- Chronic kidney disease (1)
- Chronic obstrusive pulmonary disease (1)
- Chronische Herzinsuffizienz (1)
- Chronische Nierenerkrankung (1)
- Clinical decision support system (1)
- Clinically silent stroke (1)
- Cognitive decline (1)
- Cognitive impairment (1)
- Collaboration (1)
- Coronary artery disease (1)
- Coronary heart disease (1)
- Cotransporter 2 inhibition (1)
- Cranial sutures (1)
- DSC2 (1)
- DTI (1)
- Data acquisition (1)
- Deep learning (1)
- Diagnostic medicine (1)
- Diffusion tensor imaging (1)
- Diffusionsgewichtete Magnetresonanztomografie (1)
- Dilated Cardiomyopathy with Ataxia (1)
- Diseases (1)
- Dokumentationsqualität (1)
- Double-blind (1)
- E/e’ (1)
- ERK1/2 (1)
- Echocardiography (1)
- Echokardiographie (1)
- Echtes WRF (1)
- Eigenvectors (1)
- Embryos (1)
- Endorganschaden (1)
- English version (1)
- Enhancer elements (1)
- Entscheidungsunterstützungssystem (1)
- Enzyme replacement therapy (1)
- Excitation-Transcription-Coupling (1)
- Extracellular volume (1)
- FKBP52 (1)
- Fabry Disease (FD) (1)
- Fabry-associated pain (1)
- Friedreich’s ataxia (1)
- GDNF (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Gefäßalter (1)
- Genanalyse (1)
- Germany (1)
- Glatiramer acetate (1)
- Glial fibrillary acidic protein (1)
- HFpEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Head-injury (1)
- Heart (1)
- Heart Failure (1)
- Hemodynamic depression (1)
- Herzdekompensation (1)
- Herzthoraxchirurgie (1)
- Hesse (1)
- HiGHmed (1)
- Hindbrain (1)
- Hospitalization (1)
- Hypertension (1)
- Hypertrophic cardiomyopathy (1)
- Hämodialyse (1)
- IP3 signaling (1)
- IP3-Signaling (1)
- Immunkardiologie (1)
- Immunocardiology (1)
- Immunologie (1)
- Immunophilin (1)
- Induced Pluripotent Stem Cells (1)
- Inflammation (1)
- Inositoltrisphosphat (1)
- Integrated Palliative care outcome scale (1)
- Intensivtransport (1)
- Interhospitaltransfer (1)
- Intravascular coagulation (1)
- Journal of Nuclear Cardiology (1)
- KHK (1)
- KWIC (1)
- Kandidatengen (1)
- Kardiologie (1)
- Kernspintomografie (1)
- Kognitive Defizite (1)
- Kreatinin (1)
- Künstliche Intelligenz (1)
- L-type calcium channels (1)
- LMNA (1)
- LTCC-independent function of Cavβ (1)
- LV Function (1)
- LV dilatation (1)
- LVNC (1)
- Langzeitbeatmung (1)
- Langzeitlagerung (1)
- Lebensqualität (1)
- Long COVID (1)
- MOLLI (1)
- Management (1)
- Manifestation (1)
- Massive parallele Sequenzierung (1)
- Measurement (1)
- Medicine (1)
- Mellitus (1)
- Memory dysfunction (1)
- Mice (1)
- MitoQ (1)
- Mitochondrialer Uniporter (MCU) (1)
- Mitochondrialer Uniporter Knock out (MCU-KO) (1)
- Mitofusin2 (1)
- MitraClip (1)
- Model (1)
- Molecular-weight heparin (1)
- Mortality (1)
- Mortalität (1)
- Mouse models (1)
- Mutation (1)
- Myb-MuvB (1)
- Myocardial Work (1)
- Myocardial fibrosis (1)
- Myocardial infarction (1)
- Myocardial-perfusion SPECT (1)
- Myokardinfarkt (1)
- NEC (1)
- NET (1)
- NOAC (1)
- NSG animals (1)
- NT-proBNP (1)
- NT‐proBNP (1)
- Na+/K+-ATPase (1)
- Natrium-Kalium-Pumpe (1)
- Neurodegeneration (1)
- Neurons (1)
- NfL (1)
- Niereninsuffizienz (1)
- OXPHOS (1)
- Oxygen (1)
- PKA (1)
- PKP2 (1)
- PWV (1)
- Pain questionnaire (1)
- Palliativmedizin (1)
- Placebo-controlled trial (1)
- Plasma (1)
- Prevalence (1)
- Prognostic impact (1)
- Protons (1)
- Pseudo-WRF (1)
- Pulmonary imaging (1)
- RKIP (1)
- ROS (1)
- Raman micro-spectroscopy (1)
- Rats (1)
- Risiko (1)
- Risk-factors (1)
- Röntgen-Thorax (1)
- S-glutathionylation (1)
- SAR safety (1)
- SASHA (1)
- SF-36 (1)
- SGLT2 inhibitors (1)
- SPECT (1)
- SR/Mitochondriales Feedback (1)
- ST-elevation myocardial infarction (1)
- STAAB Cohort Study (1)
- STEMI (1)
- Sars-CoV-2 (1)
- Scar (1)
- Score (1)
- Segmentation (1)
- Selbstwirksamkeit (1)
- Self-efficacy (1)
- Sengers syndrome (1)
- Septal bulge (1)
- Serum (1)
- ShMOLLI (1)
- Shimming (1)
- Skull (1)
- Somites (1)
- Spironolacton (1)
- Stabilität (1)
- Sterblichkeit (1)
- Stiffness (1)
- Stoffwechsel (1)
- Stroke (1)
- Survival (1)
- Swine (1)
- Systole (1)
- T cells (1)
- T-shaped π–π stacking (1)
- T1 mapping (1)
- T1rho (1)
- T1ρ (1)
- TMEM43 (1)
- TRPC (1)
- TRPC-Ionenkanäle (1)
- TT\(_{1rho}\) mapping (1)
- T\(_{1P}\) dispersion (1)
- T\(_{1P}\) mapping (1)
- Tabakkonsum (1)
- Tandem-Peptid (1)
- Task force (1)
- Teichholz formula (1)
- Thrombus formation (1)
- Time measurement (1)
- Tobacco smoking (1)
- Tractography (1)
- Ultrahigh field (1)
- VARS2 (1)
- Valvular heart-desease (1)
- Vaskuläre Funktion (1)
- Ventricular-arrhythmias (1)
- Verdachtsgenerierung (1)
- Versorgungsforschung (1)
- Versorgungsprogramm (1)
- WSS (1)
- Wasted Work (1)
- Weaning (1)
- Weight (1)
- YAP (1)
- Zebrafish (1)
- acid sphingomyelinase (1)
- acute decompensated heart failure (1)
- adaptive immune response (1)
- adverse effects (1)
- age-related hearing loss (1)
- akute Niereninsuffizienz (1)
- alveolar epithelium in vitro model, claudin-1, claudin-3, claudin-4, claudin-5 (1)
- amyloid cardiomyopathy (1)
- amyloidosis (1)
- anaemia (1)
- aneurysm (1)
- antenna (1)
- anti-myocardial (1)
- antibody/autoantibody (1)
- anticoagulation (1)
- antidepressants (1)
- antithrombotic therapy (1)
- anxious depression (1)
- aortic arch (1)
- aortic valve stenosis (1)
- areas (1)
- arterial stiffening (1)
- augmentation (1)
- autoantibody (1)
- basic (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure (1)
- blood pressure monitoring (1)
- blood–brain barrier (1)
- blood–labyrinth barrier (1)
- body (1)
- bolus-based perfusion measurement (1)
- bridging (1)
- cadherins (1)
- calcification (1)
- calcium cycling (1)
- calcium imaging (1)
- calcium signaling (1)
- cancer (1)
- cancer treatment (1)
- candidate genes (1)
- cardiac MRI (1)
- cardiac arrest (1)
- cardiac function (1)
- cardiac imaging (1)
- cardiac training group (1)
- cardioprotective potential (1)
- cardiovascular MR methods (1)
- cardiovascular MRI (1)
- cardiovascular drugs (1)
- cardiovascular magnetic resonance (1)
- cardiovascular magnetic resonance (CMR) (1)
- care tempis (1)
- carotid artery disease (1)
- case report (1)
- catecholamines (1)
- cell biology (1)
- cell staining (1)
- cerebral microbleeds (1)
- channel transport (1)
- chest-x-ray (1)
- cholesterol (1)
- chronic kidney disease (1)
- clinical data warehouse (1)
- clinical routine data (1)
- clinical study (1)
- clinical systems (1)
- cluster analysis (1)
- cognitive decline (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- comorbidity (1)
- comparability (1)
- computational fluid dynamics (1)
- computed tomography (1)
- conformational auto-epitope (1)
- congestion (1)
- contractility (1)
- coronary arteries (1)
- coronary artery bypass grafting (1)
- coronary artery disease (1)
- correction (1)
- cross-cultural comparison (1)
- cyclic peptides/cyclopeptides (1)
- cyclopeptide therapy (1)
- cytokines (1)
- cytotoxic T cells (1)
- data acquisition (1)
- death rates (1)
- deformation (1)
- dementia (1)
- density (1)
- depressive disorder (1)
- design (1)
- desmin-related myopathy (1)
- desminopathy (1)
- desmocollin-2 (1)
- desmoglein-2 (1)
- desmosomal mutations (1)
- diagnostic medicine (1)
- diastolic dysfunction (1)
- diastolic function (1)
- diet (1)
- digital Health (1)
- dilated cardiomyopathy with ataxia (1)
- dilated cardiomyopathy with ataxia (DCMA) (1)
- disease score (1)
- disease severity (1)
- documentation quality (1)
- drug interaction (1)
- drug intoxication (1)
- drug toxicity (1)
- eGFR (1)
- echo planar imaging (1)
- editorial (1)
- elamipretide (1)
- electromagnetics (1)
- electronic data capture (1)
- electronic health records (1)
- electrophysiology (1)
- element (1)
- endovascular treatment (1)
- enhancer (1)
- entropy production (1)
- evidence-based practice (1)
- expert opinion (1)
- fatty acids (1)
- female (1)
- filamin-C (1)
- flow dynamics (1)
- food consumption (1)
- free energy (1)
- free‐breathing (1)
- functional magnetic resonance imaging (1)
- functional mitral regurgitation (1)
- gene panel (1)
- genetics (1)
- giant intracranial aneurysm (1)
- glial damage (1)
- glomerular filtration rate (1)
- glucocorticoid replacement therapy (1)
- guideline-directed medical therapy (1)
- guidelines (1)
- haemodialysis (1)
- haemodynamic monitoring (1)
- healing and remodelling processes (1)
- health care (1)
- health policy (1)
- health-related quality of life (1)
- health‐related quality of life (1)
- heart disease (1)
- heart failure training group (1)
- heart failure with mid-range ejection fraction (1)
- heart failure with reduced ejection fraction (1)
- heart rate variability (1)
- heart structure (1)
- heart valve bypass (1)
- hemodialysis (1)
- heterozygote (1)
- high-field MRI (1)
- hospitals (1)
- human behaviour (1)
- human induced pluripotent stem cells (hiPSC) (1)
- humans (1)
- iPSC-CMs (1)
- iPSC-cardiomyocytes (1)
- iPSC-derived CMs (iPSC-CMs) (1)
- image processing (1)
- images (1)
- imaging techniques (1)
- immune cells (1)
- immunohistochemistry (1)
- immunosenescence (1)
- implementation (1)
- in vitro model system of inherited cardiomyopathies (1)
- in vivo imaging (1)
- in-vivo (1)
- induced pluripotent stem cells (iPSCs) (1)
- infarction size (1)
- infection (1)
- inferior vena cava (1)
- inflammaging (1)
- inherited cardiomyopathies (1)
- insulin tolerance test (1)
- integrated stress response (1)
- intensity of attention (1)
- intensive care transport (1)
- interhospital transfer (1)
- intermediate filaments (1)
- interparticle interaction (1)
- ischemic-stroke (1)
- junctions (1)
- kidney (1)
- kidney function (1)
- lactic acidosis (1)
- large animal models (1)
- left ventricular geometric abnormality (1)
- left ventricular geometry (1)
- left ventricular hypertrophy (1)
- left ventricular mass (1)
- left ventricular mass index (1)
- left ventricular performance (1)
- left ventricular remodeling (1)
- left ventricular thrombusv (1)
- left-ventricular function (1)
- lifestyle (1)
- linear regression analysis (1)
- long-term ventilation (1)
- low molecular heparin (1)
- lung (1)
- lymphocyte differentiation (1)
- lymphocytes (1)
- lysosomal storage disorders (1)
- m exercise training (1)
- mHealth (1)
- magnetic resoncance (1)
- major depression (1)
- management (1)
- matched filters (1)
- maturation strategies (1)
- mavacamten (1)
- meat (1)
- mechanisms (1)
- medical data integration center (1)
- medical informatics initiative (1)
- medical rehabilitation (1)
- meningioma (1)
- metabolism (1)
- metastasis (1)
- mice (1)
- middle aged (1)
- mild (1)
- mitochondria function and morphology (1)
- mitochondrial FAO (1)
- mitochondrial cardiomyopathy (1)
- mitochondrialer Ryanodin-Rezeptor (mRyR1) (1)
- mitotic genes (1)
- molecular biology (1)
- molecular imaging (1)
- molecular medicine (1)
- multivariate data analysis (1)
- music performance anxiety (1)
- mutations (1)
- myocardial aging (1)
- myocardial blood flow (1)
- myocardial perfusion reserve (1)
- myocardial work efficiency (1)
- myofilament proteins (1)
- myokardiale Arbeit (1)
- myosin (1)
- natriuretic peptide (1)
- nephrology (1)
- neuroblastoma (1)
- neurodevelopmental disorders / genetics (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- neurofilament light chain (1)
- neuroinflammation (1)
- neurological (1)
- neurology (1)
- neuroscience (1)
- neurotrophins (1)
- next generation sequencing (1)
- nicotinamide nucleotide transhydrogenase (1)
- nnU-net (1)
- non-equilibrium thermodynamics (1)
- normal values (1)
- ollimator (1)
- omecamtiv mecarbil (1)
- on-site examination (1)
- oncology (1)
- openEHR (1)
- optimization (1)
- oral anticoagulants (1)
- organoid (1)
- outcomes (1)
- oxidative stress (1)
- pCa (1)
- percutaneous mitral valve repair (1)
- pharmacotherapy (1)
- phosphorylation (1)
- pig (1)
- pilot project (1)
- plaque characteristics (1)
- plasma proteins (1)
- population-based (1)
- post-reconstruction filtering (1)
- postmenopausal women (1)
- postoperative bleeding (1)
- poultry (1)
- power grids (1)
- progressive muscle relaxation (1)
- prostate cancer (1)
- prostate-specific membrane antigen (PSMA) (1)
- public health (1)
- pulmonary artery pressure (1)
- quantitative MRI (1)
- randomized controlled trial (1)
- real-world (1)
- recovery (1)
- reference data (1)
- rehabilitation (1)
- relaxometry (1)
- religion (1)
- remote monitoring (1)
- renal (1)
- renal function (1)
- research (1)
- research infrastructure (1)
- right heart impairment (1)
- right ventricular dysfunction (1)
- risk prediction scores (1)
- rumenic acid (1)
- sacubitril-valsartan (1)
- scanner (1)
- secondary data usage (1)
- self‐gated (1)
- semantic interoperability (1)
- semantic segmentation (1)
- sensitivity analysis (1)
- sex differences (1)
- shimming (1)
- short Synacthen test (1)
- sigma-1 receptor-directed molecular imaging (1)
- signal filtering (1)
- signal to noise ratio (1)
- six-minute walk test (1)
- skeletal (1)
- skinned fiber (1)
- small animal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- social support (1)
- sodium-glucose co-transporter-2 inhibitors (1)
- somatostatin receptor (SSTR) (1)
- speckle tracking (1)
- speech recognition (1)
- sphingolipids (1)
- spin lock (1)
- spin-lock (1)
- spiral ganglion neuron (1)
- spironolactone (1)
- sports and exercise medicine (1)
- state space (1)
- statins (1)
- statistical data (1)
- statistical mechanics (1)
- stem cells (1)
- stem-cell research (1)
- stenosis (1)
- stepped impedance resonators (1)
- stroke (1)
- structure–activity relationships (1)
- study-group ADSR (1)
- sudden cardiac death (1)
- surgical aneurysm treatment (1)
- swine (1)
- sympathetic nervous system (1)
- systems biology (1)
- tandem peptide (1)
- targeted gene panel (1)
- therapy (1)
- therapy response (1)
- thermodynamics (1)
- thromboembolism (1)
- thrombolysis (1)
- time (1)
- trait emotional intelligence (1)
- transceiver array (1)
- transcription (1)
- transfer learning (1)
- transformations (1)
- transient ischemic attack (1)
- translational (1)
- ultrahigh field (1)
- ultrahigh-field (1)
- ultrahigh-field MRI (1)
- ultrasound (1)
- under-dosing (1)
- undersampling (1)
- urology (1)
- usability (1)
- user-centered design (1)
- vena contracta area (1)
- virtual reality exposure therapy (1)
- warfarin interruption (1)
- wave interference (1)
- wave‐CAIPI (1)
- weaning (1)
- zebrafish (1)
- Überleben (1)
- α-Ketoglutarate dehydrogenase (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
- βAR (1)
Institute
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (155) (remove)
Sonstige beteiligte Institutionen
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (2)
- Center for Interdisciplinary Clinical Research, Würzburg University, Würzburg, Germany (1)
- Datenintegrationszentrum Würzburg (DIZ) (1)
- Department of Medicinal Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, 1090 Vienna, Austria (1)
- Interdisziplinäre Biomaterial- und Datenbank Würzburg (ibdw) (1)
- Interdisziplinäre Zentrum für Klinische Forschung (IZKF) (1)
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) (1)
- Klinische Studienzentrale (Universitätsklinikum) (1)
- Servicezentrum Medizin-Informatik (1)
Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up.
Methods and Results
Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P<0.001), and left atrial systolic diameter (P=0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P<0.001), and significantly greater improvement in diastolic function, biomarkers, symptoms, and health status. Heart failure duration <1 year, female sex, higher predischarge blood pressure, and baseline LVEF were independent predictors of LVEF improvement. Mortality and event‐free survival rates were lower in patients with heart failure with normalized LVEF (P=0.002). Overall, LVEF increased further at 18‐months' follow‐up (P<0.001), while LV end‐diastolic diameter decreased (P=0.048). However, LVEF worsened (P=0.002) and LV end‐diastolic diameter increased (P=0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up.
Conclusions
Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling."
Despite important advances in diagnosis and treatment, heart failure (HF) remains a syndrome with substantial morbidity and dismal prognosis. Although implementation and optimization of existing technologies and drugs may lead to better management of HF, new or alternative strategies are desirable. In this regard, basic science is expected to give fundamental inputs, by expanding the knowledge of the pathways underlying HF development and progression, identifying approaches that may improve HF detection and prognostic stratification, and finding novel treatments. Here, we discuss recent basic science insights that encompass major areas of translational research in HF and have high potential clinical impact.
Growth, ageing and atherosclerotic plaque development alter the biomechanical forces acting on the vessel wall. However, monitoring the detailed local changes in wall shear stress (WSS) at distinct sites of the murine aortic arch over time has been challenging. Here, we studied the temporal and spatial changes in flow, WSS, oscillatory shear index (OSI) and elastic properties of healthy wildtype (WT, n = 5) and atherosclerotic apolipoprotein E-deficient (Apoe\(^{−/−}\), n = 6) mice during ageing and atherosclerosis using high-resolution 4D flow magnetic resonance imaging (MRI). Spatially resolved 2D projection maps of WSS and OSI of the complete aortic arch were generated, allowing the pixel-wise statistical analysis of inter- and intragroup hemodynamic changes over time and local correlations between WSS, pulse wave velocity (PWV), plaque and vessel wall characteristics. The study revealed converse differences of local hemodynamic profiles in healthy WT and atherosclerotic Apoe\(^{−/−}\) mice, and we identified the circumferential WSS as potential marker of plaque size and composition in advanced atherosclerosis and the radial strain as a potential marker for vascular elasticity. Two-dimensional (2D) projection maps of WSS and OSI, including statistical analysis provide a powerful tool to monitor local aortic hemodynamics during ageing and atherosclerosis. The correlation of spatially resolved hemodynamics and plaque characteristics could significantly improve our understanding of the impact of hemodynamics on atherosclerosis, which may be key to understand plaque progression towards vulnerability.
Aims
Heart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP)‐guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland.
Methods and results
A total of 234 NYHA class III patients (68 ± 11 years, 22% female, ≥1 HFH in the preceding year) from 31 centres were implanted with a CardioMEMS sensor and underwent PAP‐guided HF management. One‐year rates of freedom from device‐ or system‐related complications and from sensor failure (co‐primary outcomes) were 98.3% [95% confidence interval (CI) 95.8–100.0] and 99.6% (95% CI 97.6–100.0), respectively. Survival rate was 86.2%. For the 12 months post‐ vs. pre‐implant, HFHs decreased by 62% (0.60 vs. 1.55 events/patient‐year; hazard ratio 0.38, 95% CI 0.31–0.48; P < 0.0001). After 12 months, mean PAP decreased by 5.1 ± 7.4 mmHg, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall/clinical summary scores increased from 47.0 ± 24.0/51.2 ± 24.8 to 60.5 ± 24.3/62.4 ± 24.1 (P < 0.0001), and the 9‐item Patient Health Questionnaire sum score improved from 8.7 ± 5.9 to 6.3 ± 5.1 (P < 0.0001).
Conclusion
Haemodynamic‐guided HF management proved feasible and safe in the health systems of Germany, The Netherlands, and Ireland. Physician‐directed treatment modifications based on remotely obtained PAP values were associated with fewer HFH, sustainable PAP decreases, marked KCCQ improvements, and remission of depressive symptoms.
Sensitivity analysis for interpretation of machine learning based segmentation models in cardiac MRI
(2021)
Background
Image segmentation is a common task in medical imaging e.g., for volumetry analysis in cardiac MRI. Artificial neural networks are used to automate this task with performance similar to manual operators. However, this performance is only achieved in the narrow tasks networks are trained on. Performance drops dramatically when data characteristics differ from the training set properties. Moreover, neural networks are commonly considered black boxes, because it is hard to understand how they make decisions and why they fail. Therefore, it is also hard to predict whether they will generalize and work well with new data. Here we present a generic method for segmentation model interpretation. Sensitivity analysis is an approach where model input is modified in a controlled manner and the effect of these modifications on the model output is evaluated. This method yields insights into the sensitivity of the model to these alterations and therefore to the importance of certain features on segmentation performance.
Results
We present an open-source Python library (misas), that facilitates the use of sensitivity analysis with arbitrary data and models. We show that this method is a suitable approach to answer practical questions regarding use and functionality of segmentation models. We demonstrate this in two case studies on cardiac magnetic resonance imaging. The first case study explores the suitability of a published network for use on a public dataset the network has not been trained on. The second case study demonstrates how sensitivity analysis can be used to evaluate the robustness of a newly trained model.
Conclusions
Sensitivity analysis is a useful tool for deep learning developers as well as users such as clinicians. It extends their toolbox, enabling and improving interpretability of segmentation models. Enhancing our understanding of neural networks through sensitivity analysis also assists in decision making. Although demonstrated only on cardiac magnetic resonance images this approach and software are much more broadly applicable.
Purpose
Artificial neural networks show promising performance in automatic segmentation of cardiac MRI. However, training requires large amounts of annotated data and generalization to different vendors, field strengths, sequence parameters, and pathologies is limited. Transfer learning addresses this challenge, but specific recommendations regarding type and amount of data required is lacking. In this study, we assess data requirements for transfer learning to experimental cardiac MRI at 7T where the segmentation task can be challenging. In addition, we provide guidelines, tools, and annotated data to enable transfer learning approaches by other researchers and clinicians.
Methods
A publicly available segmentation model was used to annotate a publicly available data set. This labeled data set was subsequently used to train a neural network for segmentation of left ventricle and myocardium in cardiac cine MRI. The network is used as starting point for transfer learning to 7T cine data of healthy volunteers (n = 22; 7873 images) by updating the pre-trained weights. Structured and random data subsets of different sizes were used to systematically assess data requirements for successful transfer learning.
Results
Inconsistencies in the publically available data set were corrected, labels created, and a neural network trained. On 7T cardiac cine images the model pre-trained on public imaging data, acquired at 1.5T and 3T, achieved DICE\(_{LV}\) = 0.835 and DICE\(_{MY}\) = 0.670. Transfer learning using 7T cine data and ImageNet weight initialization improved model performance to DICE\(_{LV}\) = 0.900 and DICE\(_{MY}\) = 0.791. Using only end-systolic and end-diastolic images reduced training data by 90%, with no negative impact on segmentation performance (DICE\(_{LV}\) = 0.908, DICE\(_{MY}\) = 0.805).
Conclusions
This work demonstrates and quantifies the benefits of transfer learning for cardiac cine image segmentation. We provide practical guidelines for researchers planning transfer learning projects in cardiac MRI and make data, models, and code publicly available.
Impact of Interparticle Interaction on Thermodynamics of Nano-Channel Transport of Two Species
(2020)
Understanding the function and control of channel transport is of paramount importance for cell physiology and nanotechnology. In particular, if several species are involved, the mechanisms of selectivity, competition, cooperation, pumping, and its modulation need to be understood. What lacks is a rigorous mathematical approach within the framework of stochastic thermodynamics, which explains the impact of interparticle in-channel interactions on the transport properties of the respective species. To achieve this, stochastic channel transport of two species is considered in a model, which different from mean field approaches, explicitly conserves the spatial correlation of the species within the channel by analysis of the stochastic dynamics within a state space, the elements of which are the channel’s spatial occupation states. The interparticle interactions determine the stochastic transitions between these states. Local flow and entropy production in this state space reveal the respective particle flows through the channel and the intensity of the Brownian ratchet like rectifying forces, which these species exert mutually on each other, together with its thermodynamic effectiveness and costs. Perfect coupling of transport of the two species is realized by an attractive empty channel and strong repulsive forces between particles of the same species. This confines the state space to a subspace with circular topology, in which the concentration gradients as thermodynamic driving forces act in series, and channel flow of both species becomes equivalent. For opposing concentration gradients, this makes the species with the stronger gradient the driving, positive entropy producing one; the other is driven and produces negative entropy. Gradients equal in magnitude make all flows vanish, and thermodynamic equilibrium occurs. A differential interparticle interaction with less repulsive forces within particles of one species but maintenance of this interaction for the other species adds a bypass path to this circular subspace. On this path, which is not involved in coupling of the two species, a leak flow of the species with less repulsive interparticle interaction emerges, which is directed parallel to its concentration gradient and, hence, produces positive entropy here. Different from the situation with perfect coupling, appropriate strong opposing concentration gradients may simultaneously parallelize the flow of their respective species, which makes each species produce positive entropy. The rectifying potential of the species with the bypass option is diminished. This implies the existence of a gradient of the other species, above which its flow and gradient are parallel for any gradient of the less coupled species. The opposite holds for the less coupled species. Its flow may always be rectified and turned anti-parallel to its gradient by a sufficiently strong opposing gradient of the other one.
Chronische Nierenerkrankungen gehen mit einer erhöhten kardiovaskulären Morbidität und Mortalität einher. Charakteristisch für chronische Nierenerkrankungen, insbesondere im Stadium der Dialysepflichtigkeit, ist eine ausgeprägte Voralterung der Gefäße. Die Vorgänge, die den beschleunigten vaskulären Alterungsprozessen zugrunde liegen, umfassen ein Zusammenspiel aus einem gestörten Mineralstoffwechsel, der Akkumulation urämischer Toxine und chronischer Inflammation. Das Renin-Angiotensin-Aldosteron-System (RAAS) nimmt dabei eine zentrale Rolle ein. Eine gesteigerte Aktivität des RAAS ist ein Merkmal von kardiorenalen Syndromen und moduliert jenseits seiner Effekte auf den Blutdruck vaskuläre Entzündungs- und Remodelingprozesse. Durch das vaskuläre Altern kommt es zur Abnahme arterieller Compliance und zur Erhöhung der Pulswellengeschwindigkeit (PWV). Dadurch erhöht sich das Risiko für Endorganschäden. Die arterielle Gefäßsteifigkeit ist ein unabhängiger Prädiktor für Mortalität bei chronisch-dialysepflichtiger Niereninsuffizienz und eine Reduktion arterieller Rigidität geht mit einem verbesserten Überleben einher. Randomisierte Studien bei Dialysepatienten konnten bislang keinen eindeutigen Nutzen etablierter pharmakologischer Interventionen zur Reduktion des kardiovaskulären Risikos und vaskulärer «Stiffeningprozesse» feststellen. Als ein potentiell wirksamer Therapieansatz werden Mineralokortikoidrezeptorantagonisten (MRA) angesehen. Die vorliegende Arbeit evaluierte im Rahmen der Placebo-kontrollierten, randomisierten «Mineralocorticoid-Receptor Antagonists in End-Stage Renal Disease» (MiREnDa) Studie, ob die tägliche Einnahme von 50 mg Spironolacton über neun Monate einen Effekt auf die vaskuläre Funktion bei Patienten mit dialysepflichtiger chronischer Nierenerkrankung hat. Neben aortaler PWV, Augmentationsindex, zentralem Puls- und Blutdruck wurden zur Evaluation der vaskulären Funktion die Compliance der thorakalen Aorta und der A. carotis communis sowie die Distensibilität der A. carotis communis und die fluss-vermittelte Dilatation der A. brachialis vor Studienbeginn als sekundäre Endpunkte festgelegt. Ein weiterer Aspekt, der evaluiert wurde, war die Frage nach Korrelationen zwischen PWV und Augmentationsindex einerseits und weiteren Parametern vaskulärer Funktion, klinischen Merkmalen und Biomarkern andererseits. Die vorliegende Arbeit versuchte darüber hinaus, klinische Merkmale (Komorbiditäten, Inflammation), die ein Therapieansprechen von MRA potentiell modulieren, zu identifizieren. Das zentrale Ergebnis der Arbeit war, dass eine MRA-Therapie mit 50 mg Spironolacton täglich über neun Monate im untersuchten Kollektiv keinen Effekt auf die vaskuläre Funktion zeigte.
Background
Performance anxiety is the most frequently reported anxiety disorder among professional musicians. Typical symptoms are - on a physical level - the consequences of an increase in sympathetic tone with cardiac stress, such as acceleration of heartbeat, increase in blood pressure, increased respiratory rate and tremor up to nausea or flush reactions. These symptoms can cause emotional distress, a reduced musical and artistical performance up to an impaired functioning. While anxiety disorders are preferably treated using cognitive-behavioral therapy with exposure, this approach is rather difficult for treating music performance anxiety since the presence of a public or professional jury is required and not easily available. The use of virtual reality (VR) could therefore display an alternative. So far, no therapy studies on music performance anxiety applying virtual reality exposure therapy have investigated the therapy outcome including cardiovascular changes as outcome parameters.
Methods
This mono-center, prospective, randomized and controlled clinical trial has a pre-post design with a follow-up period of 6 months. 46 professional and semi-professional musicians will be recruited and allocated randomly to an VR exposure group or a control group receiving progressive muscle relaxation training. Both groups will be treated over 4 single sessions. Music performance anxiety will be diagnosed based on a clinical interview using ICD-10 and DSM-5 criteria for specific phobia or social anxiety. A behavioral assessment test is conducted three times (pre, post, follow-up) in VR through an audition in a concert hall. Primary outcomes are the changes in music performance anxiety measured by the German Bühnenangstfragebogen and the cardiovascular reactivity reflected by heart rate variability (HRV). Secondary outcomes are changes in blood pressure, stress parameters such as cortisol in the blood and saliva, neuropeptides, and DNA-methylation.
Discussion
The trial investigates the effect of VR exposure in musicians with performance anxiety compared to a relaxation technique on anxiety symptoms and corresponding cardiovascular parameters. We expect a reduction of anxiety but also a consecutive improvement of HRV with cardiovascular protective effects.
Trial registration
This study was registered on clinicaltrials.gov. (ClinicalTrials.gov Number: NCT05735860)
Background
Right ventricular dysfunction after CABG is associated with poor peri- and postoperative outcomes. We aimed to identify clinical and experimental predictors for preoperative inapparent right ventricular dysfunction and therefore hypothesized that reduced myofilament force development as well as altered levels of biomarkers might predict inapparent right ventricular dysfunction.
Methods
From 08/2016 to 02/2018, 218 patients scheduled for CABG were divided into two groups (TAPSE ≥ 20 mm, n = 178; TAPSE < 20 mm, n = 40). Baseline serum samples for biomarkers (Galectin, TGFß1, N Acyl-SDMA, Arginine, ADMA and Pentraxin-3), clinical laboratory and transthoracic echocardiographic parameters were evaluated. To examine the myocardial apparatus of the right ventricle intraoperative right auricular tissue was harvested for stepwise skinned fiber force measurements.
Results
Patients with TAPSE < 20 mm had a higher incidence of DM (55 vs. 34%, p = 0.018), preoperative AFib (43 vs. 16%, p < 0.001), reduced GFR (67 ± 18 vs. 77 ± 24 ml/min/1.73 m\(^2\), p = 0.013), larger LA area (22 ± 6 vs. 20 ± 5 cm\(^2\), p = 0.005) and reduced LVEF (50 vs. 55%, p = 0.008). Furthermore, higher serum ADMA (0.70 ± 0.13 vs. 0.65 ± 0.15 µmol/l, p = 0.046) and higher serum Pentraxin-3 levels (3371 ± 1068 vs. 2681 ± 1353 pg/dl, p = 0.004) were observed in these patients. Skinned fiber force measurements showed significant lower values at almost every step of calcium concentration (pCa 4.52 to pCa 5.5, p < 0.01 and pCa 5.75–6.0, p < 0.05). Multivariable analysis revealed DM (OR 2.53, CI 1.12–5.73, Euro Score II (OR 1.34, CI 1.02–1.78), preoperative AF (OR 4.86, CI 2.06–11.47), GFR (OR 7.72, CI 1.87–31.96), albumin (OR 1.56, CI 0.52–2.60), Pentraxin-3 (OR 19.68, CI 14.13–25.24), depressed LVEF (OR 8.61, CI 6.37–10.86), lower force values: (pCa 5.4; OR 2.34, CI 0.40–4.29 and pCa 5.2; OR 2.00, CI 0.39–3.60) as predictors for clinical inapparent right heart dysfunction.
Conclusions
These preliminary data showed that inapparent right heart dysfunction in CAD is already associated with reduced force development of the contractile apparatus.
Although heart failure following myocardial infarction (MI) represents a major health burden, underlying microstructural and functional changes remain incompletely understood. Here, we report on a case of unexpected MI after treatment with the catecholamine isoproterenol in an experimental imaging study in mice using different state-of-the-art imaging modalities. The decline in cardiac function was documented by ultrahigh-frequency echocardiography and speckle-tracking analyses. Myocardial microstructure was studied ex vivo at a spatial resolution of 100 × 100 × 100 μm\(^{3}\) using diffusion tensor magnetic resonance imaging (DT-MRI) and histopathologic analyses. Two weeks after ISO treatment, the animal showed an apical aneurysm accompanied by reduced radial strain in corresponding segments and impaired global systolic function. DT-MRI revealed a loss of contractile fiber tracts together with a disarray of remaining fibers as corresponding microstructural correlates. This preclinical case report provides valuable insights into pathophysiology and morphologic–functional relations of heart failure following MI using emerging imaging technologies.
Mitochondria are central organelles in the homeostasis of the cardiovascular system via the integration of several physiological processes, such as ATP generation via oxidative phosphorylation, synthesis/exchange of metabolites, calcium sequestration, reactive oxygen species (ROS) production/buffering and control of cellular survival/death. Mitochondrial impairment has been widely recognized as a central pathomechanism of almost all cardiovascular diseases, rendering these organelles important therapeutic targets. Mitochondrial dysfunction has been reported to occur in the setting of drug-induced toxicity in several tissues and organs, including the heart. Members of the drug classes currently used in the therapeutics of cardiovascular pathologies have been reported to both support and undermine mitochondrial function. For the latter case, mitochondrial toxicity is the consequence of drug interference (direct or off-target effects) with mitochondrial respiration/energy conversion, DNA replication, ROS production and detoxification, cell death signaling and mitochondrial dynamics. The present narrative review aims to summarize the beneficial and deleterious mitochondrial effects of common cardiovascular medications as described in various experimental models and identify those for which evidence for both types of effects is available in the literature.
The transcription factor 12 (tcf12) is a basic Helix-Loop-Helix protein (bHLH) of the E-protein family, proven to play an important role in developmental processes like neurogenesis, mesoderm formation, and cranial vault development. In humans, mutations in TCF12 lead to craniosynostosis, a congenital birth disorder characterized by the premature fusion of one or several of the cranial sutures. Current research has been primarily focused on functional studies of TCF12, hence the cellular expression profile of this gene during embryonic development and early stages of ossification remains poorly understood. Here we present the establishment and detailed analysis of two transgenic tcf12:EGFP fluorescent zebrafish (Danio rerio) reporter lines. Using these transgenic lines, we analyzed the general spatiotemporal expression pattern of tcf12 during different developmental stages and put emphasis on skeletal development and cranial suture patterning. We identified robust tcf12 promoter-driven EGFP expression in the central nervous system (CNS), the heart, the pronephros, and the somites of zebrafish embryos. Additionally, expression was observed inside the muscles and bones of the viscerocranium in juvenile and adult fish. During cranial vault development, the transgenic fish show a high amount of tcf12 expressing cells at the growth fronts of the ossifying frontal and parietal bones and inside the emerging cranial sutures. Subsequently, we tested the transcriptional activity of three evolutionary conserved non-coding elements (CNEs) located in the tcf12 locus by transient transgenic assays and compared their in vivo activity to the expression pattern determined in the transgenic tcf12:EGFP lines. We could validate two of them as tcf12 enhancer elements driving specific gene expression in the CNS during embryogenesis. Our newly established transgenic lines enhance the understanding of tcf12 gene regulation and open up the possibilities for further functional investigation of these novel tcf12 enhancer elements in zebrafish.
Objective: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. Participants: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence.
Consensus Process: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments.
Conclusions: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 mu g) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (similar to 8 mg/m\(^2\)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
Restrictive cardiomyopathy is a rare cardiac disease causing severe diastolic dysfunction, ventricular stiffness and dilated atria. In consequence, it induces heart failure often with preserved ejection fraction and is associated with a high mortality. Since it is a poor clinical prognosis, patients with restrictive cardiomyopathy frequently require heart transplantation. Genetic as well as non-genetic factors contribute to restrictive cardiomyopathy and a significant portion of cases are of unknown etiology. However, the genetic forms of restrictive cardiomyopathy and the involved molecular pathomechanisms are only partially understood. In this review, we summarize the current knowledge about primary genetic restrictive cardiomyopathy and describe its genetic landscape, which might be of interest for geneticists as well as for cardiologists.
About 50% of patients with arrhythmogenic cardiomyopathy (ACM) carry a pathogenic or likely pathogenic mutation in the desmosomal genes. However, there is a significant number of patients without positive familial anamnesis. Therefore, the molecular reasons for ACM in these patients are frequently unknown and a genetic contribution might be underestimated. Here, we used a next-generation sequencing (NGS) approach and in addition single nucleotide polymor-phism (SNP) arrays for the genetic analysis of two independent index patients without familial medical history. Of note, this genetic strategy revealed a homozygous splice site mutation (DSG2–c.378+1G>T) in the first patient and a nonsense mutation (DSG2–p.L772X) in combination with a large deletion in DSG2 in the second one. In conclusion, a recessive inheritance pattern is likely for both cases, which might contribute to the hidden medical history in both families. This is the first report about these novel loss-of-function mutations in DSG2 that have not been previously identi-fied. Therefore, we suggest performing deep genetic analyses using NGS in combination with SNP arrays also for ACM index patients without obvious familial medical history. In the future, this finding might has relevance for the genetic counseling of similar cases.
Here, we present a small Iranian family, where the index patient received a diagnosis of restrictive cardiomyopathy (RCM) in combination with atrioventricular (AV) block. Genetic analysis revealed a novel homozygous missense mutation in the DES gene (c.364T > C; p.Y122H), which is absent in human population databases. The mutation is localized in the highly conserved coil-1 desmin subdomain. In silico, prediction tools indicate a deleterious effect of the desmin (DES) mutation p.Y122H. Consequently, we generated an expression plasmid encoding the mutant and wildtype desmin formed, and analyzed the filament formation in vitro in cardiomyocytes derived from induced pluripotent stem cells and HT-1080 cells. Confocal microscopy revealed a severe filament assembly defect of mutant desmin supporting the pathogenicity of the DES mutation, p.Y122H, whereas the wildtype desmin formed regular intermediate filaments. According to the guidelines of the American College of Medical Genetics and Genomics, we classified this mutation, therefore, as a novel pathogenic mutation. Our report could point to a recessive inheritance of the DES mutation, p.Y122H, which is important for the genetic counseling of similar families with restrictive cardiomyopathy caused by DES mutations.
Oxidative stress is defined as an imbalance between the antioxidant defense system and the production of reactive oxygen species (ROS). At low levels, ROS are involved in the regulation of redox signaling for cell protection. However, upon chronical increase in oxidative stress, cell damage occurs, due to protein, DNA and lipid oxidation. Here, we investigated the oxidative modifications of myofilament proteins, and their role in modulating cardiomyocyte function in end-stage human failing hearts. We found altered maximum Ca\(^{2+}\)-activated tension and Ca\(^{2+}\) sensitivity of force production of skinned single cardiomyocytes in end-stage human failing hearts compared to non-failing hearts, which was corrected upon treatment with reduced glutathione enzyme. This was accompanied by the increased oxidation of troponin I and myosin binding protein C, and decreased levels of protein kinases A (PKA)- and C (PKC)-mediated phosphorylation of both proteins. The Ca\(^{2+}\) sensitivity and maximal tension correlated strongly with the myofilament oxidation levels, hypo-phosphorylation, and oxidative stress parameters that were measured in all the samples. Furthermore, we detected elevated titin-based myocardial stiffness in HF myocytes, which was reversed by PKA and reduced glutathione enzyme treatment. Finally, many oxidative stress and inflammation parameters were significantly elevated in failing hearts compared to non-failing hearts, and corrected upon treatment with the anti-oxidant GSH enzyme. Here, we provide evidence that the altered mechanical properties of failing human cardiomyocytes are partially due to phosphorylation, S-glutathionylation, and the interplay between the two post-translational modifications, which contribute to the development of heart failure.
Die Na+ /K+ -ATPase (NKA) ist maßgeblich an der Regulation der kardialen Na+ -Homöostase beteilligt. Im Myokard werden hauptsächlich zwei Isoformen exprimiert: die α1 (NKA-α1) und die α2-Isoform (NKA-α2). Diese beiden Isoformen unterscheiden sich sowohl in ihrer Lokalisation als auch in ihrer zellulären Funktion. So ist die NKA-α1 recht homogen entlang des Sarkolemms zu finden und ist verantwortlich für die Regulation der globalen intrazellulären Na+ -Konzentration ([Na+ ]i). Die NKA-α2 hingegen konzentriert sich hauptsächlich in den T-Tubuli und beeinflusst über Veränderung der lokalen [Na+ ]i die Ca2+ -Transienten und die Kontraktilität. Im Rahmen einer Herzinsuffizienz wurde eine verminderte Expression und Aktivität der NKA beobachtet. Gleichzeitig werden Inhibitoren der NKA, sogenannte Digitalisglykoside, in fortgeschrittenen Herzinsuffizienz-Stadien eingesetzt. Die Studienlage über den Einsatz dieser Therapeutika ist recht uneinheitlich und reicht von einer verringerten Hospitalisierung bis hin zu einer erhöhten Mortalität. Ziel dieser Arbeit war es die Folgen einer NKA-α2 Aktivierung während einer Herzinsuffizienz mit Hilfe eines murinen Überexpressionsmodells zu analysieren. 11-Wochen alte Mäuse mit einer kardialen NKA-α2 Überexpression (NKA-α2) und Wildtyp (WT) Versuchstiere wurden einem 8-wöchigen Myokardinfarkt (MI) unterzogen. NKA-α2 Versuchstiere waren vor einem pathologischem Remodeling und einer kardialen Dysfunktion geschützt. NKA-α2 Kardiomyozyten zeigten eine erhöhte Na+ /Ca2+ -Austauscher (NCX) Aktivität, die zu niedrigeren diastolischen und systolischen Ca2+ -Spiegeln führte und einer Ca2+ -Desensitisierung der Myofibrillen entgegenwirkte. WT Versuchstiere zeigten nach chronischem MI eine sarkoplasmatische Ca2+ -Akkumulation, die in NKA-α2 Kardiomyozyten ausblieb. Gleichzeitig konnte in der NKA-α2 MI Kohorte im Vergleich zu den WT MI Versuchstieren eine erhöhte Expression von β1-adrenergen Rezeptoren (β1AR) beobachtet werden, die eine verbesserte Ansprechbarkeit gegenüber β-adrenergen Stimuli bewirkte. Zudem konnte in unbehandelten Versuchstieren eine Interaktion zwischen NKA-α2 und dem β1AR nachgewiesen werden, welche in der WT Kohorte größer ausfiel als in der NKA-α2 Versuchsgruppe. Gleichzeitig zeigten unbehandelte NKA-α2 Kardiomyozyten eine erhöhte Sensitivität gegenüber β-adrenerger Stimulation auf, welche nicht mit einer erhöhten Arrhythmie-Neigung oder vermehrten Bildung reaktiver Sauerstoffspezies einherging. Diese Untersuchungen zeigen, dass eine NKA-α2 Überexpression vor pathologischem Remodeling und einer kardialen Funktionbeeinträchtigung schützt, indem eine systolische, diastolische und sarkoplasmatische Ca2+ -Akkumulation verhindert wird. Gleichzeitig wird die β1AR Expression stabilisert, wodurch es zu einer verminderten neurohumoralen Aktivierung und einer Durchbrechung des Circulus vitiosus kommen könnte. Insgesamt scheint eine Aktivierung der NKA-α2 durchaus ein vielversprechendes Target in der Herzinsuffizienz Therapie darzustellen.
Therapie darzustellen.